Wolfson Diabetes and Endocrinology Clinic, Institute of Metabolic Science, Cambridge University Hospitals NHS Foundation Trust, Addenbrookes Hospital, Cambridge, UK.
Best Pract Res Clin Endocrinol Metab. 2010 Aug;24(4):625-34. doi: 10.1016/j.beem.2010.05.002.
Metformin lowers blood glucose by reducing hepatic glucose output, increasing insulin sensitivity and enhancing peripheral glucose uptake. Metformin is widely used in women with Type 2 diabetes of child-bearing age, many of whom become pregnant. Studies to date in Type 2 diabetes in pregnancy, gestational diabetes and polycystic ovarian syndrome are reassuring. Metformin is not considered teratogenic. There is sufficient evidence that metformin is safe used throughout pregnancy, with no worsening of obstetric or perinatal outcomes. Women may benefit from the lesser weight gain. The long-term risks to the offspring remain inadequately researched, with no evidence of harm up to 2 years, and no suggestions of later complications in countries using metformin for many years. Metformin is recommended for use in pregnancies complicated by Type 2 diabetes, but women should be informed of the evidence regarding its associated risks and benefits to enable an informed choice over its use.
二甲双胍通过减少肝葡萄糖输出、增加胰岛素敏感性和促进外周葡萄糖摄取来降低血糖。二甲双胍广泛用于有生育能力的 2 型糖尿病女性,其中许多人会怀孕。迄今为止,在 2 型糖尿病妊娠、妊娠期糖尿病和多囊卵巢综合征中的研究结果令人放心。二甲双胍不被认为有致畸性。有充分的证据表明,二甲双胍在整个怀孕期间使用是安全的,不会恶化产科或围产期结局。女性可能会受益于体重增加减少。对子代的长期风险研究不足,在使用二甲双胍多年的国家,2 年内没有发现任何危害的证据,也没有后期并发症的提示。二甲双胍推荐用于 2 型糖尿病合并妊娠,但应告知妇女其相关风险和益处的证据,以便在使用该药时做出知情选择。